Clearmind Medicine advances its neuroplastogen‑based addiction therapy after completing Part A of an FDA‑regulated Phase I/II trial
Executive summary: Clearmind Medicine completed Part A of its FDA‑regulated Phase I/II trial for its nonhallucinogenic neuroplastogen‑derived treatment aimed at Alcohol Use Disorder, addiction and weight management. Meeting Part A’s safety and tolerability milestones clears the way for Part B, where efficacy will be tested, potentially accelerating the path toward clinical proof‑of‑concept for a novel AUD therapy.
Who is involved: Clearmind Medicine (Nasdaq: CMND), the FDA (providing trial oversight), clinical investigators and trial participants.
Likely next: The company will initiate Part B of the trial to evaluate efficacy and further safety, with top‑line results expected later in 2026 or early 2027.
On July 28 2026, Clearmind Medicine announced that it had finished Part A of its FDA‑regulated Phase I/II trial for a nonhallucinogenic neuroplastogen‑derived treatment targeting Alcohol Use Disorder, addiction and weight management. The completion indicates that the preliminary safety and tolerability objectives were met, allowing the company to move toward the efficacy‑focused Part B. No safety concerns were disclosed in the release.
Timeline
- — Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial (GlobeNewswire)
Analysis — what this means
Likely next events
- Clearmind to initiate Part B of the Phase I/II trial in Q4 2026
- Top‑line efficacy data from Part B expected by Q1 2027
- Potential submission of an IND amendment or meeting with FDA to discuss Phase II design by mid‑2027
Sectors affected
- Alcohol Use Disorder therapeutics
- Neuroplastogen‑based addiction treatments
- Biotechnology clinical trials
Historical parallels
- 3D Systems obtains first FDA clearance for a point‑of‑care implant (GlobeNewswire, July 28 2026)
- Dyne Therapeutics receives FDA IND clearance for DYNE‑302 in FSHD (GlobeNewswire, July 28 2026)
- Cullinan Therapeutics reports positive end‑of‑Phase 1 meeting with FDA for CLN‑049 in AML (GlobeNewswire, July 28 2026)
Key entities
Sources
- Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial — GlobeNewswire
Related cases
- Karmanos Cancer Institute begins offering the newly FDA‑approved KRAS G12C inhibitor daraxonrasib (Rasonque) for metastatic pancreatic cancer, marking the first clinical rollout of a targeted therapy for a historically hard‑to‑treat malignancy
- FDA clears Caliway's CBL-514 combo with tirzepatide for Phase 2 trial as pivotal Phase 3 SUPREME-01 starts enrollment
- FDA’s approval of IMAAVY provides the first-ever drug for warm autoimmune hemolytic anemia, creating a new niche in rare disease therapeutics
- FDA approves Implantica's RefluxStop, clearing the way for US market entry of a new GERD treatment device
- FDA approval clears the way for Implantica’s RefluxStop to enter the U.S. GERD treatment market
- AbelZeta regains global rights to C‑CAR039 (Prizlon‑cel) and secures FDA IND clearance for large B‑cell lymphoma therapy